Trial Profile
The Effect of Obesity in Dexmedetomidine Metabolic Clearance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Cancer pain; Pain; Sedation; Subarachnoid haemorrhage
- Focus Pharmacokinetics
- 01 May 2018 Status changed from active, no longer recruiting to completed, according to the results published in the British Journal of Anaesthesia.
- 01 May 2018 Results published in the British Journal of Anaesthesia
- 11 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.